Rituximab vs intravenous methylprednisolone
NOSPECS improvement (decrease) by 2 classes or more · thyroid‐associated ophthalmopathy
It is very uncertain whether summary of findings table ‐ Rituximab changes NOSPECS improvement (decrease) by 2 or more classes compared with intravenous methylprednisolone (very low certainty).
1 finding from 1 review
- RR 1.07 [0.25, 4.49]1 study · 31 participantsVery low